SMMT vs TAP · $11.46B cap vs rev $13.04B
Summit Therapeutics PLC (SMMT) versus TAP (TAP) — a side-by-side from cached financials, not a winner call.
Summit Therapeutics PLC (SMMT) is a biotechnology company listed on US.
TAP (TAP) common stock.
SMMT does not have a complete income-statement cache yet.
Latest reported TAP revenue for 2025-12-31 was $13.04B. Net income was -$2.14B. Revenue was down 5.1% from 2024-12-31 to 2025-12-31. TAP currently screens at market cap $0.
SMMT currently screens at market cap $11.46B. TAP currently screens at market cap $0.
Not investment advice. Open the SMMT and TAP stock pages for the full models.
Not investment advice.